Cargando…
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
In this phase II, multicentre trial, patients with metastatic breast cancer (MBC) were treated with a combination of gemcitabine, epirubicin and paclitaxel (GET). The primary objective of this study was to determine the tolerability and activity in terms of complete responce (CR) and overall respons...
Autores principales: | Cappuzzo, F, Mazzoni, F, Gennari, A, Donati, S, Salvadori, B, Orlandini, C, Cetto, G L, Molino, A, Galligioni, E, Mansutti, M, Tumolo, S, Lucentini, A, Valduga, F, Bartolini, S, Crinò, L, Conte, P F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395340/ https://www.ncbi.nlm.nih.gov/pubmed/14710202 http://dx.doi.org/10.1038/sj.bjc.6601518 |
Ejemplares similares
-
Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
por: Baldini, E, et al.
Publicado: (2004) -
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
por: Conte, P F, et al.
Publicado: (2005) -
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
por: Gennari, A, et al.
Publicado: (2004) -
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005) -
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)